Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes

NCT01923181 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01923181
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01923181 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
December 2, 2013
Completion date
December 11, 2014
Enrollment
632 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2